Statistical analysis plan (SAP) for MEDIC

Total knee replacement plus physical and medical therapy or treatment with physical and medical therapy alone: a randomised controlled trial in patients with knee osteoarthritis (the MEDIC-study)

Skou, Søren Thorgaard; Roos, Ewa M.; Laursen, Mogens Berg; Rathleff, Michael Skovdal; Arendt-Nielsen, Lars; Simonsen, Ole; Rasmussen, Søren

Publication date:
2014

Document Version
Early version, also known as pre-print

Link to publication from Aalborg University

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
? You may not further distribute the material or use it for any profit-making activity or commercial gain
? You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from vbn.aau.dk on: October 28, 2019
STATISTICAL ANALYSIS PLAN (SAP) FOR:

THE MEDIC-STUDY
- Total knee replacement plus physical and medical therapy or treatment with physical and medical therapy alone: a randomised controlled trial in patients with knee osteoarthritis (the MEDIC-study)

Study chair:
Søren Thorgaard Skou, PhD-student\textsuperscript{1,2} (Principal investigator, Corresponding author)
Ewa M Roos, PhD, Professor\textsuperscript{3}
Mogens Berg Laursen, MD, PhD\textsuperscript{1}
Michael S. Rathleff, PhD\textsuperscript{4}
Lars Arendt-Nielsen, DMS\textsuperscript{c}, PhD, Professor\textsuperscript{2}
Ole Simonsen, MD, DMS\textsuperscript{1}
Sten Rasmussen, MD, Associate Professor\textsuperscript{1,2}

Statistical advisor:
Martin Berg Johansen, MSc\textsuperscript{5}
Jonas Ranstam, Professor\textsuperscript{6}

\textsuperscript{1}Orthopaedic Surgery Research Unit, Aalborg University Hospital, Aalborg, Denmark
\textsuperscript{2}Department of Health Science and Technology, Centre for Sensory-Motor Interaction, Aalborg University, Aalborg, Denmark
\textsuperscript{3}Research Unit for Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark
\textsuperscript{4}Department of Occupational Therapy and Physiotherapy, Aalborg University Hospital, Aalborg, Denmark
\textsuperscript{5}Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
\textsuperscript{6}Lund University and Skane University Hospital, Lund, Sweden
Table of contents

1. Study Synopsis .......................................................................................................................... 3

2. Study Objectives and Outcomes .............................................................................................. 3
   2.1. Primary Objective and Outcome ......................................................................................... 3
   2.2. Secondary Objectives and Outcomes ................................................................................. 4
   2.3. Exploratory Objectives ..................................................................................................... 5
   2.4. Economic Evaluation ......................................................................................................... 6
   2.5. Descriptive Outcomes ....................................................................................................... 7
   2.6. Specification of endpoints .................................................................................................. 7
       2.6.1. Primary Endpoint ....................................................................................................... 7
       2.6.2. Secondary Endpoints .................................................................................................. 8

3. Study Design .......................................................................................................................... 9
   3.1. Sample Size ..................................................................................................................... 9
   3.2. Randomization and Blinding ............................................................................................ 9

4. Study Population ................................................................................................................. 10
   4.1. Subject Disposition ......................................................................................................... 10

5. Statistical Analysis ............................................................................................................... 11
   5.1. Primary Endpoint ............................................................................................................ 11
   5.2. Secondary Endpoints ..................................................................................................... 11
   5.3. Major Protocol Deviations .............................................................................................. 11

6. Implementation of Analysis Plan ....................................................................................... 12

7. References ............................................................................................................................ 13

8. Tables .................................................................................................................................... 15
   8.1. Table 1. Adverse Events .................................................................................................. 15
   8.2. Table 2. Baseline characteristics ..................................................................................... 17
   8.3. Table 3. Treatment-related variables ............................................................................... 19
   8.4. Table 4. Outcome at 1 year ........................................................................................... 20


1. Study Synopsis

Knee osteoarthritis (OA) is a major cause of chronic pain and a leading cause of functional disability in the elderly. Total knee arthroplasty (TKA) is considered an effective treatment in end-stage knee OA, but the indications have broadened to include younger patients and patients with less severe symptoms. This highlights the demand for consensus on the indication for TKA in knee OA and requires the development of high quality evidence for the treatment options in knee OA. This randomized, controlled trial aims at investigating whether TKA provides further improvement in addition to a 12-week non-surgical treatment program (MEDIC; neuromuscular exercise, patient education, weight loss (if needed), insoles and medicine) in patients eligible for a TKA (Figure 1).

Patients fulfilling the eligibility criteria, but refusing to participate in the randomization, were offered to participate in an observational cohort, were they were able to choose which of the two treatment options they wanted. They followed the same intervention, follow-up schedule and study endpoints as patients in the randomized controlled trial, but were analyzed separately.

2. Study Objectives and Outcomes

A study protocol elaborating the methods used in this study has been published. All outcomes were obtained from all participants at baseline and all follow-ups (3months, 6months and 12months; Figure 1). The 12month follow-up is expected to be finalized in February 2015.

2.1. Primary Objective and Outcome

The primary objective is to compare the change from baseline to the 1 year follow-up (including all follow-ups) between patients randomized to the MEDIC-treatment or TKA + the MEDIC-treatment in the average score of four of the five subscales from the Knee Injury and Osteoarthritis Outcome Score (KOOS) covering pain, symptoms, activities of daily living (ADL), and knee-related quality of life (QOL).

An overall KOOS-score can be used as primary endpoint in an RCT, if defined a priori. However, the purpose of an overall score (KOOS) as the primary endpoint is to avoid issues with multiplicity. Since an overall score has not been subjected to psychometric validation the individual KOOS subscales must be analyzed as secondary outcomes to enable clinical interpretation of the contributions of the individual subscales to the overall KOOS score.

The reason for not including the KOOS subscale Sports & recreation function (Sport/Rec) in the primary endpoint KOOS was that it was expected that a large proportion of the participants in this study would not perform the activities assessed in this subscales (running, jumping, squatting, kneeling and pivoting). This could potentially affect the content validity, which is why it was excluded from the aggregated primary outcome.
Each item in KOOS is scored from 0-4 on a Likert scale. Subscale scores are given separately (see www.koos.nu for user’s guide and scoring) ranging from 0 [worst] to 100 [best]. KOOS has previously been validated for patients eligible for TKA \(^8,9\). Each subscale of the primary outcome of this study, KOOS\(_4\), will be calculated according to the instructions in the user’s guide. After that an average of the four subscales will be calculated giving each subscale equally large impact on the KOOS\(_4\) score using this formula:

\[
KOOS_4 = \frac{(KOOS \text{ Pain} + KOOS \text{ Symptoms} + KOOS \text{ ADL} + KOOS \text{ QOL})}{4}
\]

### 2.2. Secondary Objectives and Outcomes

The secondary objectives are to compare change from baseline to the 1 year follow-up (including all follow-ups) between groups in a range of outcomes. These outcomes will only be supportive, explanatory and/or hypothesis generating, which is why multiplicity is not considered to be a problem\(^10\).

The outcomes are (arranged hierarchically according to their importance):

1) The five subscales of KOOS:
   a. Symptoms
   b. Pain
   c. ADL
   d. Sport/Rec
   e. QOL

2) Functional performance
   a. Time from the Timed Up and Go \(^{12}\)
   b. Time from the 20-meter walk test \(^{13}\)

3) The descriptive system (EQ-5D Index) and the EQ VAS (0-100) from the Euro-Quality-of-Life – 5 Dimensional form (EQ-5D-3L) \(^{11}\).

4) Weight change in percent measured without shoes at the same time of day and on the same scale (seca 813, seca gmbh & co. kg., Hamburg, Germany)

5) Usage of pain killers during the last week (yes/no), number of weekly paracetamols (1g) and ibuprofen (400mg) and other NSAIDs.

6) Adverse events (AE) and seriously adverse events (SAE) will be registered in three ways and divided into index knee or sites other than index knee. The project physiotherapist will record any adverse events that the participant experiences or tells them about. For the participants allocated to, or crossing over to, TKA, a project worker will look
through hospital records to register if any pre-defined perioperative and postoperative adverse events occurred. At all follow-ups, the assessor will use open-probe questioning to assess adverse events in all participants (Table 1).

### 2.3. Exploratory Objectives

The exploratory objectives are to compare change from baseline to the 1 year follow-up (including all follow-ups) between groups in a range of outcomes. These outcomes will only be exploratory and/or hypothesis generating, which is why multiplicity is not considered to be a problem.

The outcomes are:

1) Pain intensities on a 100 mm VAS with terminal descriptors of ‘no pain’ and ‘worst pain possible’ in the following situations: at rest, at night, after 50 m of walking, after 30 min. of walking, after exercise/physical activity, during preferred physical activity, and worst pain and least pain in the previous 24 hours.

2) Number of sites with pain in the previous 24 hours shaded on a region-divided body chart.

3) Pain location and type assessed using the reliable interviewer-administered questionnaire Knee Pain Map.

4) Maximum isometric muscle strength (converted to Nm using the length of the lower leg) measured bilaterally in knee flexion and knee extension in a make test using a handheld dynamometer (Powertrack II™ Commander from JTech Medical Industries, Salt Lake City, Utah, USA).

5) Pressure pain thresholds measured bilaterally using a handheld algometer (Algometer Type II, Somedic AB, Hoerby, Sweden) at five sites at the knee and the m. tibialis anterior muscle.

6) Self-efficacy in improving pain, function and QOL in various situations using a 100 mm VAS with terminal descriptors of ‘very unsure’ and ‘very sure’.

Additionally, an analysis will be conducted to investigate if treatment compliance (see section 2.5.) is associated with the change in KOOS.

Based on recent studies in similar patient populations, an exploratory analysis applying a 15% difference in change in KOOS between groups from baseline to the 1 year follow-up as the Minimal Important Change (MIC; see section 2.6.) will be conducted.

An analysis of Number Needed to Treat (NNT) will be performed. NNT estimates the number of people who would need to go through the TKA + MEDIC-treatment for one person to have a MIC (15%) in KOOS from baseline to the 12 month follow-up compared to the MEDIC-treatment alone.
Furthermore changes in the following exploratory outcomes from baseline to 3 months will be compared between groups to investigate the effects on pain sensitization: 1), 2), 3), and 5).

The test setup for muscle strength and pressure pain thresholds will be assessed in a study of test-retest reliability of 20 knee OA patients.

Further exploratory objectives may be added later on.

2.4. Economic Evaluation
The EQ-5D will be applied in a health economic evaluation\textsuperscript{11}.

Figure 1: Flow chart
2.5. Descriptive Outcomes

Baseline characteristics will be presented in a table (Table 2).

Furthermore, the following treatment-related variables will be presented descriptively:

1) Compliance with exercise will be recorded by the physiotherapist during the 12 weeks. Compliance is assessed as the total number of exercise sessions completed out of the total 24 sessions (two sessions a week over twelve weeks). Good compliance is defined as participation in 75 % or more of the exercise sessions, moderate compliance as participation in 50-74 % of the sessions and poor compliance as participation in less than 50 % of the sessions.

2) Compliance with insoles, patient education and dietary advice will be assessed at each follow-up, using a five-point scale assessing the adherence to the treatment (never, every month, every week, every day, all the time).

3) Satisfaction with the treatment effect will be registered at each follow-up on a five-point Likert scale (very dissatisfied, dissatisfied, neither satisfied nor dissatisfied, satisfied, very satisfied). Surgery during the 12 month follow-up period will also be registered (Table 3).

2.6. Specification of endpoints

2.6.1. Primary Endpoint

The primary outcome (KOOS4) will be analyzed in intent-to-treat (ITT) and per-protocol (PP) analyses.

The ITT population will be defined as those randomized to the two treatment arms.

The PP population will be defined as those who participated in the MEDIC-treatment with at least 75% compliance with the exercise during the 12 week intervention period and stayed in the treatment arm allocated by randomization during the 1 year period. This means that the following will be excluded from the PP analysis:

1) Those who did not participate in all aspects of the MEDIC-treatment;

2) Those participating in below 75% of the exercise sessions

3) Those who were randomized to treatment according to the MEDIC-treatment alone but had an TKA during the 1 year period; and

4) Those who were randomized to TKA + the MEDIC-treatment, but decided not to undergo surgery anyway

Treatment effect will be determined as change in the primary outcome KOOS4 from baseline to the 1 year follow-up (see section 5.1.).

The trial is designed as a superiority trial, i.e. we expect that the group allocated to TKA in addition to the MEDIC-treatment will improve at least 10 points more than the group allocated
to MEDIC-treatment in the primary outcome KOOS₄ and the individual KOOS subscales from baseline to the primary endpoint after 1 year.

The 1 year follow-up was chosen as the primary endpoint, since this is the time when the largest improvements are reported after TKA after which outcomes seems to decline ¹⁸.

Since KOOS contains the full and original version of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), it has been suggested to apply a MIC of 10 points, which has been demonstrated for WOMAC ¹⁹. Recent studies in similar patient populations ¹⁶, ¹⁷ have applied a MIC of 15%. However, percentage change from baseline is not recommended as an outcome in controlled trials, since it has low statistical power, is highly sensitive to changes in variance and fails to protect from bias in the case of baseline imbalance ²⁰. We acknowledge that MIC is dependent on context factors such as population, intervention, and time to follow-up ²¹, which is why we will conduct an exploratory analysis applying a 15% difference in change in KOOS₄ and the individual KOOS subscales between groups from baseline to the 1 year follow-up as the MIC.

Based on the mentioned shortcoming with percent change as the outcome in controlled trials, we decided to maintain the 10 point MIC in KOOS₄ and the individual KOOS subscales in this study. Therefore, the sample size calculation was based on 90% power to detect a 10 point difference between groups in KOOS₄ after 1 year, which will be used to define the superiority margin (Δ=10points).

Superiority will be tested using the two-sided 95% confidence interval (CI) of the mean change in KOOS₄ between the two treatment groups. Treatment according to TKA + the MEDIC-treatment will be considered superior to the MEDIC-treatment when the lower side of this 95% CI excludes the superiority margin (Δ).

### 2.6.2. Secondary Endpoints

Secondary endpoints will be analyzed for between group differences using ITT and PP analyses (see section 5.2.).

Each subscale of the KOOS will be presented graphically for its development over the 1 year period.

Each subscale of the KOOS, time (s) in Timed Up and Go, time (s) in 20-meter walk test, EQ-5D Index, EQ VAS, weight (kg) and self-efficacy will be presented as mean (95% CI) for each treatment group, while usage of pain killers will be presented as actual numbers and proportions. Between group differences in change from baseline to 1 year will be statistically assessed. The analysis for weight will only be conducted for participants with BMI≥25.

All issues during the trial found in the treatment records from the project physiotherapist, hospital records or the questionnaire from the follow-ups will be assessed to determine whether it represents an AE or not. AE will be presented in a table (see Table 1) and analyzed statistically by comparing actual numbers of serious AE (site other than index knee, index knee
and all serious events) and non-serious AE (site other than index knee, index knee and all serious events). Besides being analyzed according to ITT and PP, AE will be analyzed in an as treated analysis separating those undergoing TKA during the 1 year and those who did not. The two groups are defined using the following criteria:

**AE associated with TKA:**

1. Those receiving TKA by randomization
2. All treatment dependent AE reported after TKA in those who had TKA even though randomized to the MEDIC-treatment alone throughout the follow up period

**AE associated with treatment according to a rehabilitation program alone:**

1. Those remaining in the ‘Rehabilitation alone’ group throughout the follow up period
2. All treatment dependent AE reported prior to the TKA in those who had TKA even though randomized to the MEDIC-treatment alone

### 3. Study Design

#### 3.1. Sample Size

We used a common between-subject standard deviation of 14 to calculate the sample size needed to detect a 10 point difference in KOOS4 and the individual KOOS subscales (power of 90 % and significance level at 0.05 (twosided)). The calculations showed that 41 participants were required in each group.

To account for crossovers and missing data, the drop-out rate was set to 20 % and therefore, a total of 100 participants were randomized.

#### 3.2. Randomization and Blinding

The schedule for randomization was randomly generated using a computer before the initiation of the trial. The randomization was by random permuted blocks, stratified according to the clinic (Frederikshavn or Farsoe) to control for variation in patient characteristics in the two clinics. To conceal the outcomes of the randomisation, the allocation numbers were put in concealed, opaque C5 envelopes. In blocks of eight, these envelopes were placed in consecutively numbered opaque larger envelopes (seven larger envelopes in total for each clinic). An independent staff member prepared the envelopes. These were kept in a locked location accessible only by one research assistant at each of the respective clinics. Following the informed consent and completion of the baseline measures, a smaller envelope from the numbered larger envelopes was opened by the research assistant and the allocation revealed to the participant. When only two smaller envelopes were left in the first of the numbered larger envelopes, the smaller envelopes of the second larger envelope were added. When there were
six smaller envelopes left in the sixth of the numbered larger envelopes at each clinic, the last two of the smaller envelopes were added.

The outcome assessor is blinded to group allocation, is not involved in providing the interventions, and is unaffiliated with the treatment sites. The participants and the project physiotherapist delivering part of the interventions could not be blinded. The statistician performing the statistical analyses will be blinded to group allocation.

The writing committee of this study (identical to the study chair in this SAP) will, prior to breaking the code, conduct two interpretations of the results on the basis of a blinded review of the data from the primary endpoint (changes from treatment A compared to changes from treatment B), one assuming that treatment A is TKA + the MEDIC-treatment, and the other assuming that treatment A is the MEDIC-treatment alone. Not until the writing committee has agreed that there will be no further changes in the interpretation the randomization code will broken, ensuring that bias in the interpretation is reduced.

4. Study Population

4.1. Subject Disposition

Study procedures, including recruitment strategies and inclusion and exclusion criteria, have been published previously in a study protocol. Patient included in the trial were randomized to:

A) TKA + the MEDIC-treatment (Medicine, neuromuscular Exercise, Diet (if needed), Insoles and Cognitive treatment (patient education)) or B) MEDIC-treatment alone. No patients fulfilling all eligibility criteria could be excluded.

Patients fulfilling the eligibility criteria, but refusing to participate in the randomization, were offered to participate in an observational cohort, were they were able to choose which of the two treatment options they wanted. They followed the same intervention, follow-up schedule and study endpoints as patients in the randomized controlled trial, but were analyzed separately.

Crossovers are a common problem in studies randomizing to surgical or non-surgical treatment. In this study participants who experienced impairment of their symptoms or lack of improvement during the 12week MEDIC-treatment were reassessed by the orthopaedic surgeon who assessed them in the recruitment phase. Pre-defined criteria for crossover to TKA or re-surgery in TKA-patients are a score for QOL and/or for Pain equal to or below 25 on the KOOS and/or agreement between the participant and the orthopaedic surgeon that a TKA or re-surgery is necessary. This defined treatment failure in the study.

The frequency of crossover to TKA, revision TKA and other surgeries will be registered and reported (Table 3).
5. Statistical Analysis

5.1. Primary Endpoint

The between-group difference in change in KOOS₄ from baseline to 1 year follow-up will be the primary outcome, complemented by the individual KOOS subscales assessing pain, symptoms, ADL function and Quality of Life to allow for clinical in-depth interpretation.

Between groups comparisons of treatment effect (change in KOOS₄ from baseline to 1 year follow-up) will be dependent on data distribution. We expect the change to be normally distributed and analysis will be made using a mixed model ANOVA with subject being a random factor and visit (baseline, 3, 6 and 12 months), treatment arm (TKA + MEDIC, MEDIC) and site (Frederikshavn, Farsoe) being fixed factors. Baseline KOOS₄ will be a covariate. Furthermore interactions between the fixed factors will be included in the model. P-values and 95% CI will be presented to assess superiority.

5.2. Secondary Endpoints

Between groups comparisons of change from baseline to the 1 year follow-up in the secondary endpoints will be handled similar to the primary endpoint, except for adverse events that will be analyzed using a Poisson regression model with robust error variance for the CI.

5.3. Major Protocol Deviations

In the study protocol we decided to apply a generalized estimating equations regression model (GEE) to analyze KOOS₄ to take all follow-ups into account. However, since improvements in the two groups are not expected to follow the same pattern (It is expected that the TKA + MEDIC-treatment will have smaller improvement at the 3 months follow-up, but will have improved more at the 12 months follow-up compared to the MEDIC-treatment alone group) the GEE is not suitable for the analyses. The application of this method could potentially result in that between group differences at the 12 months follow-up were diminished due to differences in the opposite direction at the 3 or 6 months follow-up. Furthermore, the sample size calculation was based on the change from baseline to 12 months and not the change over several different follow-ups. After consulting with several statisticians, the authors decided to change the method of analyses for all endpoints to a mixed model ANOVA, which is the most suitable method to investigate changes from baseline to 12 months taking baseline values into account. A mixed model ANOVA is conditional (subject-specific opposite to a GEE that is population-specific) and enables inclusion of the entire full analysis set (defined as an analysis set being as complete and as close to the ITT-principles of including all randomized patients as possible) as even with an unbalanced dataset. Furthermore, the authors believe that the application of this method makes the results and the conclusion of the study easier to understand and interpret. Since this SAP is published before the 12 months follow-up is complete (February 2015) and
any analyses have been performed, the change in method of statistical analyses will not induce any bias.

6. Implementation of Analysis Plan

This SAP will be used as a work description for the statistician performing the analyses. All analyses will be performed by the same statistician and none of the investigators involved in this trial will perform any of the statistical analyses.

The implementation of the SAP will be as follows:

1. A ‘data collection form’ will be outlined in a collaboration between the database manager, statistician and principal investigator (Søren Thorgaard Skou).

2. The database manager will code each treatment arm into ‘treatment A’ and ‘treatment B’ and thus leaving all others blinded from treatment during the analyses.

3. Blinded data will be delivered to the statistician according to the ‘data collection form’.

4. Primary, secondary and exploratory endpoint analyses will be made blinded from treatment.

5. Results will be presented to the writing committee of the trial (identical to the study chair in this SAP) where any uncertainties will be clarified and blinded interpretations of the primary endpoint results will be conducted prior to unblinding of data.
7. References


10. The European Agency for the Evaluation of Medicinal Products, CPMP. Points to consider on multiplicity issues in clinical trials. EMEA 2002:.


8. Tables

8.1. Table 1. Adverse Events

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>MEDIC</th>
<th>Usual Care</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of events</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Serious events**
- Site other than index knee
- Musculoskeletal
- Skin
- Gastrointestinal
- Other

**Index knee**
- Pain
- Swelling
- Subjective instability
- Decreased range of motion
- Distortion
- Other

**During surgery**
- Patella fracture
- Tibia fracture
- Femur fracture
- Rupture of the patella tendon
- Other

**Postoperatively**
- Arthrofibrosis
- Deep infection
- Surgery demanding skin necrosis
- Surgery demanding scar tissue adherences
- Thrombophlebitis in demand of anticoagulant treatment
- Patella sub-/luxation
- Supra-condylar femur fracture
- Permanent n. peroneus paresis
<table>
<thead>
<tr>
<th>Pulmonary embolism</th>
<th>Patella fracture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aseptic loosening</td>
<td>Polyethylene defect (tibia)</td>
</tr>
<tr>
<td>Polyethylene defect (patella)</td>
<td>Secondary insertion of patella component</td>
</tr>
<tr>
<td>Instability</td>
<td>Pain without loosening</td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
</tbody>
</table>

**All serious events**

**Nonserious events**

<table>
<thead>
<tr>
<th>Sites other than index knee</th>
<th>Index knee</th>
</tr>
</thead>
<tbody>
<tr>
<td>All nonserious events</td>
<td></td>
</tr>
</tbody>
</table>
### 8.2. Table 2. Baseline characteristics

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>MEDIC</th>
<th>Usual Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years), mean (SD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight (kg), mean (SD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body Mass Index, mean (SD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OA in right knee, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of knee symptoms, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-12 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-2 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-5 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-10 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>More than 10 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiographic knee OA severity (Kellgren-Lawrence), n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Charlson Comorbidity Index, median (iqr)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Living alone, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>College education or equivalent, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employment status, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Working full-time or part-time</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sick leave</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pensioner</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior treatment of knee OA, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercise</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physiotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paracetamol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSAIDs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cortisone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injection</td>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Menisci with surgery</td>
<td>Knees with debridement</td>
<td></td>
</tr>
<tr>
<td>Knees with other surgery</td>
<td>Others</td>
<td></td>
</tr>
</tbody>
</table>

**KOOS scores**

<table>
<thead>
<tr>
<th>KOOS</th>
<th>KOOS4</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Pain</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADL</td>
<td>Sport/Rec</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>QOL</th>
<th>EQ-5D, mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EQ-5D Index</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EQ VAS</th>
<th>Functional performance, mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Time (s) from the Timed Up and Go</td>
</tr>
<tr>
<td></td>
<td>Time (s) from the 20-meter walk test</td>
</tr>
<tr>
<td></td>
<td>Have used pain killers in the last week (n (%))</td>
</tr>
</tbody>
</table>


### 8.3. Table 3. Treatment-related variables

<table>
<thead>
<tr>
<th>Variable</th>
<th>MEDIC</th>
<th>MEDIC + TKA</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compliance with exercise during the 12 weeks, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Usage of the other aspects of the treatment program at least every day at the 3month follow-up, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insoles</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient education</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dietary advice</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery during follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TKA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days from randomization, mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Re-TKA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days from randomization, mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brisement Forcé</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days from randomization, mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days from randomization, mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total number of surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Satisfied with the treatment effects after 12months</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
8.4. Table 4. Outcome at 1 year

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Improvement in MEDIC-group</th>
<th>Improvement in MEDIC + TKA-group</th>
<th>Between-group difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (months) follow-up after start of MEDIC-treatment (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary endpoint: mean change in KOOS4 from baseline to 1 yr (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary Endpoints</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean change in KOOS subscales score (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sport/Rec</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QOL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean change in time (s) from the Timed Up and Go (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean change in time (s) from the 20-meter walk test (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean change in EQ-5D (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EQ-5D Index</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EQ VAS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean weight change (kg; 95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in participants using</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pain killers in the last week (n (%))</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>